Litcius/Paper detail

Endoscopic Screening for Second Primary Tumors of the Esophagus Among Head and Neck Cancer Patients

Chen‐Shuan Chung, Li‐Jen Liao, Chia‐Yun Wu, Wu‐Chia Lo, Chen-Hsi Hsieh, Tzong-His Lee, Chun‐Yu Liu, Deng‐Yu Kuo, Pei‐Wei Shueng

2022Frontiers in Oncology20 citationsDOIOpen Access PDF

Abstract

Malignancies of the head and neck (HN) region and esophagus are among the most common cancers worldwide. Due to exposure to common carcinogens and the theory of field cancerization, HN cancer patients have a high risk of developing second primary tumors (SPTs). In our review of 28 studies with 51,454 HN cancer patients, the prevalence of SPTs was 12%. The HN area is the most common site of SPTs, followed by the lungs and esophagus, and 13% of HN cancer patients have been reported to have esophageal high-grade dysplasia or invasive carcinoma. The prognosis of HN cancer patients with concomitant esophageal SPTs is poor, and therefore identifying esophageal SPTs as early as possible is of paramount importance for risk stratification and to guide the treatment strategy. Image-enhanced endoscopy, especially using narrow-band imaging endoscopy and Lugol's chromoendoscopy, has been shown to improve the diagnostic performance in detecting esophageal neoplasms at an early stage. Moreover, the early detection and minimally invasive endoscopic treatment of early esophageal neoplasm has been shown to improve the prognosis. Well-designed prospective studies are warranted to establish appropriate treatment and surveillance programs for HN cancer patients with esophageal SPTs.

Topics & Concepts

MedicineField cancerizationEsophagusChromoendoscopyEsophageal cancerHead and neck cancerDysplasiaEsophageal NeoplasmCancerEndoscopyRadiologyStage (stratigraphy)Internal medicineGastroenterologyOncologyColonoscopyColorectal cancerPaleontologyBiologyEsophageal Cancer Research and TreatmentMetastasis and carcinoma case studiesLung Cancer Diagnosis and Treatment
Endoscopic Screening for Second Primary Tumors of the Esophagus Among Head and Neck Cancer Patients | Litcius